268 related articles for article (PubMed ID: 17975152)
1. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
Armstrong AJ; Garrett-Mayer ES; Yang YC; de Wit R; Tannock IF; Eisenberger M
Clin Cancer Res; 2007 Nov; 13(21):6396-403. PubMed ID: 17975152
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Armstrong AJ; Garrett-Mayer E; Ou Yang YC; Carducci MA; Tannock I; de Wit R; Eisenberger M
J Clin Oncol; 2007 Sep; 25(25):3965-70. PubMed ID: 17761981
[TBL] [Abstract][Full Text] [Related]
3. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Garrett-Mayer E; de Wit R; Tannock I; Eisenberger M
Clin Cancer Res; 2010 Jan; 16(1):203-11. PubMed ID: 20008841
[TBL] [Abstract][Full Text] [Related]
4. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
Armstrong AJ; Tannock IF; de Wit R; George DJ; Eisenberger M; Halabi S
Eur J Cancer; 2010 Feb; 46(3):517-25. PubMed ID: 20005697
[TBL] [Abstract][Full Text] [Related]
5. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
6. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
Halabi S; Lin CY; Small EJ; Armstrong AJ; Kaplan EB; Petrylak D; Sternberg CN; Shen L; Oudard S; de Bono J; Sartor O
J Natl Cancer Inst; 2013 Nov; 105(22):1729-37. PubMed ID: 24136890
[TBL] [Abstract][Full Text] [Related]
7. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
Sonpavde G; Pond GR; Berry WR; de Wit R; Armstrong AJ; Eisenberger MA; Tannock IF
Urol Oncol; 2012 Sep; 30(5):607-13. PubMed ID: 20888271
[TBL] [Abstract][Full Text] [Related]
8. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Tannock IF; de Wit R; Berry WR; Horti J; Pluzanska A; Chi KN; Oudard S; Théodore C; James ND; Turesson I; Rosenthal MA; Eisenberger MA;
N Engl J Med; 2004 Oct; 351(15):1502-12. PubMed ID: 15470213
[TBL] [Abstract][Full Text] [Related]
11. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
12. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
[TBL] [Abstract][Full Text] [Related]
13. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Van Poppel H
Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
Petrylak DP; Ankerst DP; Jiang CS; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
J Natl Cancer Inst; 2006 Apr; 98(8):516-21. PubMed ID: 16622120
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy in hormone-refractory prostate cancer.
de Wit R
BJU Int; 2008 Mar; 101 Suppl 2():11-5. PubMed ID: 18307687
[TBL] [Abstract][Full Text] [Related]
16. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
Font A; Murias A; Arroyo FR; Martin C; Areal J; Sanchez JJ; Santiago JA; Constenla M; Saladie JM; Rosell R
Ann Oncol; 2005 Mar; 16(3):419-24. PubMed ID: 15668260
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients.
Oudard S; Banu E; Scotte F; Banu A; Medioni J; Beuzeboc P; Joly F; Ferrero JM; Goldwasser F; Andrieu JM
Ann Oncol; 2007 Nov; 18(11):1828-33. PubMed ID: 17846024
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
[TBL] [Abstract][Full Text] [Related]
20. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
Guinney J; Wang T; Laajala TD; Winner KK; Bare JC; Neto EC; Khan SA; Peddinti G; Airola A; Pahikkala T; Mirtti T; Yu T; Bot BM; Shen L; Abdallah K; Norman T; Friend S; Stolovitzky G; Soule H; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Xie Y; Aittokallio T; Zhou FL; Costello JC;
Lancet Oncol; 2017 Jan; 18(1):132-142. PubMed ID: 27864015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
